Biotech Layoff Wave Hits Karyopharm, Century, and Pacira in 2025
biotech layoffs; Karyopharm Therapeutics; Century Therapeutics; Pacira; 2025 workforce reductions; biopharma restructuring
EU Lifts Restriction on Valneva’s Chikungunya Vaccine for Older Adults, Recommends Caution
Valneva; Chikungunya vaccine; IXCHIQ; European Medicines Agency; older adults; safety concerns; label extension; adverse events
FDA Rejects Capricor’s Cell Therapy for Duchenne Muscular Dystrophy
FDA rejection; Capricor Therapeutics; deramiocel; Duchenne muscular dystrophy; DMD; cell therapy; cardiomyopathy; clinical data; Phase 3 HOPE-3 trial; Complete Response Letter
Bayer’s Lynkuet (elinzanetant) Wins First-in-World Approval in UK, Challenging Astellas’ Hot Flash Drug
Bayer; elinzanetant; Lynkuet; menopause; hot flashes; vasomotor symptoms; Astellas; non-hormonal therapy; MHRA approval; UK first approval
Apple Watch AI Model Enhances Health Predictions Using Behavioral Data
Apple Watch; AI model; behavioral data; health prediction; machine learning; Wearable Behavior Model; pregnancy detection; Heart and Movement Study
FDA Commissioner Makary Proposes Fast-Track Drug Review Vouchers Tied to Lower US Prices, Without Detailing Criteria
FDA; Makary; national priority review vouchers; drug pricing; fast-track approval; price parity; pilot program
Moderna’s COVID Vaccine Wins FDA Approval for At-Risk Young Children
Moderna; FDA approval; COVID vaccine; children; at-risk; Spikevax; underlying conditions; full approval
Biopharma Layoffs Continue to Surge in First Half of 2025
biopharma; layoffs; 2025; workforce reductions; industry trends; biotech closures; year-over-year increase
UnitedHealth Group Names Mike Cotton as New Medicaid CEO in Executive Reshuffle
UnitedHealth Group; CEO appointment; Medicaid; Mike Cotton; executive changes; government programs; Bobby Hunter; leadership transition
AbbVie Acquires Rights to Ichnos Glenmark’s Lead Myeloma Antibody (ISB 2001) in $1.93 Billion Deal
AbbVie; Ichnos Glenmark; ISB 2001; trispecific antibody; multiple myeloma; biotech deal; CD3; BCMA; CD38; Phase 1 clinical trial; global licensing; oncology